Termine
Performance
01.12.2021

03.12.21 Hibbett Sports, Inc. 
Analysts' Conference
03.12.21 TK Elevator GmbH
Analysts' Conference
03.12.21 Aurubis AG
Veröffentlichung Jahresfinanzbericht
02.12.21 Befesa S.A.
Analystenveranstaltung
02.12.21 Befesa S.A.
Analystenveranstaltung
02.12.21 Vonovia SE
Pressekonferenz
02.12.21 Dollar General Corporation
Analysts' Conference
02.12.21 Siemens Energy AG
Analystenveranstaltung
02.12.21 Instone Real Estate Group SE
Roadshow
02.12.21 KWS SAAT SE & Co. KGaA
Hauptversammlung
02.12.21 Scout24 SE
Analystenveranstaltung
02.12.21 Deutsche Beteiligungs AG
Veröffentlichung Jahresfinanzbericht
01.12.21 VMware, Inc.
Analysts' Conference
01.12.21 VMware, Inc.
Analysts' Conference
01.12.21 Vonovia SE
Analystenveranstaltung
01.12.21 TPI Composites, Inc.
Analystenveranstaltung
01.12.21 Semtech Corporation
Analystenveranstaltung
01.12.21 B+S Banksysteme Aktiengesellschaft
Hauptversammlung
01.12.21 Deutsche EuroShop AG
DZ Bank Equity Conference, Frankfurt
01.12.21 CLIQ Digital AG
Roadshow

Dezember

KW M D M D F S S
48     1 2 3 4 5
49 6 7 8 9 10 11 12
50 13 14 15 16 17 18 19
51 20 21 22 23 24 25 26
52 27 28 29 30 31    

Januar 2022

KW M D M D F S S
52           1 2
1 3 4 5 6 7 8 9
2 10 11 12 13 14 15 16
3 17 18 19 20 21 22 23
4 24 25 26 27 28 29 30
5 31            

Februar 2022

KW M D M D F S S
5   1 2 3 4 5 6
6 7 8 9 10 11 12 13
7 14 15 16 17 18 19 20
8 21 22 23 24 25 26 27
9 28            

 

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

01. Dezember 2021